Van Eck Associates Corp Allogene Therapeutics, Inc. Transaction History

Van Eck Associates Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$3.17 - $5.96 $1,176 - $2,211	371 Added 18.87%	2,337 $7,000
Q2 2023 Aug 03, 2023	SELL	$4.53 - $6.74 $1,096 - $1,631	-242 Reduced 10.96%	1,966 $10,000
Q1 2023 May 03, 2023	SELL	$4.92 - $8.21 $1,589 - $2,651	-323 Reduced 12.76%	2,208 $11,000
Q4 2022 Feb 08, 2023	BUY	$5.62 - $11.11 $3,894 - $7,699	693 Added 37.7%	2,531 $16,000
Q3 2022 Oct 27, 2022	BUY	$10.32 - $17.28 $18,968 - $31,760	1,838 New	1,838 $20,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.